Cargando…

Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer

PURPOSE: The human EGFR2 (HER2) signaling pathway is one of the most actively studied targets in cancer transformation research. Ttriplex-forming oligonucleotides (TFOs) activate DNA damage and induce apoptosis. We aim to encapsulate TFO-HER2 with nano-particle ZW-128 to suppress breast cell growth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiaojing, Xu, Yi, Fu, Jie, Shen, Zan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357592/ https://www.ncbi.nlm.nih.gov/pubmed/37468837 http://dx.doi.org/10.1186/s12885-023-11176-8

Ejemplares similares

TFOS lifestyle: Impact of societal challenges on the ocular surface
por: Stapleton, Fiona, et al.
Publicado: (2023)

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
por: Yang, Xiaojing, et al.
Publicado: (2023)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

Engineering of Neutrophil Membrane Camouflaging Nanoparticles Realizes Targeted Drug Delivery for Amplified Antitumor Therapy
por: Wang, Jingshuai, et al.
Publicado: (2021)

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy
por: Floros, Konstantinos V., et al.
Publicado: (2018)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022)

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
por: Niza, Enrique, et al.
Publicado: (2019)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
por: Li, Jun, et al.
Publicado: (2017)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Transcriptome and genome evolution during HER2-amplified breast neoplasia
por: Lu, Peipei, et al.
Publicado: (2021)

Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells
por: Dietel, Eric, et al.
Publicado: (2018)

Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles
por: Satpathy, Minati, et al.
Publicado: (2019)

HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
por: Nakamura, Yoshiaki, et al.
Publicado: (2019)

Glutathione‐Scavenging Nanoparticle‐Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects
por: Liu, Hai‐Jun, et al.
Publicado: (2023)

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
por: Sitia, Leopoldo, et al.
Publicado: (2022)

Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines
por: Blakney, Anna K., et al.
Publicado: (2021)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
por: Dent, Susan F., et al.
Publicado: (2021)

New Advances in Targeted Therapy of HER2-Negative Breast Cancer
por: An, Junsha, et al.
Publicado: (2022)

Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells
por: Matevossian, Armine, et al.
Publicado: (2015)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
por: Dou, Xiao-qian, et al.
Publicado: (2018)

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
por: Garay, Joseph P., et al.
Publicado: (2021)

Redox Potential Ultrasensitive Nanoparticle for the Targeted Delivery of Camptothecin to HER2-Positive Cancer Cells
por: K.C., Remant Bahadur, et al.
Publicado: (2014)

Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
por: Fu, Zhaoying, et al.
Publicado: (2020)

CuS@BSA-NB2 Nanoparticles for HER2-Targeted Photothermal Therapy
por: Ying, Ming, et al.
Publicado: (2022)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Targeted therapy for HER2 positive breast cancer
por: Incorvati, Jason A, et al.
Publicado: (2013)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
por: Mann, K, et al.
Publicado: (2016)

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
por: Staaf, Johan, et al.
Publicado: (2011)

Nanoparticle-Mediated Targeted Drug Delivery to Remodel Tumor Microenvironment for Cancer Therapy
por: Tang, Lu, et al.
Publicado: (2021)

Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
por: Park, Soon Young, et al.
Publicado: (2023)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma
por: Wang, Qinyang, et al.
Publicado: (2022)

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
por: Yousefpour, Parisa, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9338do5449ka6d2hptoo1metsv